Australia approves new drug to treat early Alzheimer’s disease

Australia’s approval of Donanemab marks a significant first step toward treating early Alzheimer’s disease, offering hope for those eligible but facing high costs and limited access. The drug targets amyloid protein buildup, slowing disease progression by one-third, yet only about 10-20% of people with dementia qualify due to genetic factors. costing over $80,000 out of pocket, it is not covered by insurance or PBS, despite Eli Lilly's efforts to include it on the Pharmaceutical Benefits Scheme for specific cases. Early diagnosis and specialized testing are required, adding significant financial and medical burdens.